Journal
CELL REPORTS MEDICINE
Volume 1, Issue 3, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xcrm.2020.100040
Keywords
-
Categories
Funding
- Emory EVPHA Synergy Fund award
- National Institutes of Health NIAID Infectious Diseases Clinical Research Consortium (IDCRC) [UM1 AI148684, R01 AI137127, ORIP/OD P51OD011132, 5T32 AI074492, R00 AG049092]
- Marcus Foundation
- World Reference Center for Emerging Viruses and Arboviruses [R24 AI120942]
- HIPC [5U19AI090023-10]
- VTEU [1UM1AI148576-01]
Ask authors/readers for more resources
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available